Treatment of erythrodermic cutaneous T-cell lymphoma with intermittent chlorambucil and fluocortolone therapy

British Journal of Dermatology

Volumn 143, Issue 1, 2000, Pages 127-131

  Coors, E A ^a   Von Den Driesch, P ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Chemotherapy; Cutaneous T cell lymphoma; Open pilot study; Pulsed treatment; Sezary syndrome

Indexed keywords

CHLORAMBUCIL; FLUOCORTOLONE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; ERYTHRODERMA; FEMALE; FOLLOW UP; HUMAN; MALE; PILOT STUDY; PRIORITY JOURNAL; REMISSION; SEZARY SYNDROME; SKIN LYMPHOMA; T CELL LYMPHOMA; TREATMENT OUTCOME;

AGED; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; CHLORAMBUCIL; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; FLUOCORTOLONE; GLUCOCORTICOIDS; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; PILOT PROJECTS; PULSE THERAPY, DRUG; SKIN NEOPLASMS;

EID: 0033913909     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2000.03601.x     Document Type: Article

References (14)

1. Winkelmann RK, Diaz Ferez JL, Buechner SA. The treatment of Sézary syndrome. J Am Acad Dermatol 1984; 10: 1000-4.
2. Sawitsky A, Rai KR, Glidewell 0, Silver RT. Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood 1977; 50: 1049-59.
3. Pegourie Bandelier B, Sotto JJ, Hollard D et al. Therapy program for patients with advanced stages of chronic lymphocytic leukemia. Chlorambucil, splenectomy, and total lymph node irradiation. Cancer 1995; 75: 2853-61.
4. Knospe WH, Loeb VJ. Huguley CMJ. Bi-weekly chlorambucil treatment of chronic lymphocytic leukemia. Cancer 1974; 33: 555-62.
5. Hoppe RT, Wood GS, Abel EA. Mycosis fungoides and the Sézary syndrome: pathology, staging, and treatment. Ciirr Probl Cancer 1990; 14: 293-371.
6. Lorincz AL. Cutaneous T-cell lymphoma (mycosis fungoides). Lancet 1996; 347: 871-6.
7. Wieselthier JS, Koh HK. Sézary syndrome: diagnosis, prognosis, and critical review of treatment options. J Am Acad Dermatol 1990; 22: 381-401.
8. Kim YH, Bishop K, Varghese A, Hoppe RT. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. Arch Dermatol 1995; 131: 1003-8.
9. Zackheim HS, Epstein E. Low-dose methotrexate for Sézary syndrome. J Am Acad Dermatol 1989; 21: 757-62.
10. Gottlieb SL, Wolfe JT, Fox FE et al. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with'.recombinant interferon alfa: a 10-year experience at a single institution. J Am Acad Dermatol 1996; 35: 946-57.
11. Duvic M, Hester], Lemak N. Photopheresis therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1996; 35: 573-9.
12. Zic JA, Stricklin GP, Gréer JP et al. Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy. J Am Acad Dermatol 1996; 35: 935-45.
13. Fraser Andrews E, Seed P, Whittaker S, Russell Jones R. Extracorporeal photopheresis in Sézary syndrome. No significant effect in the survival of 44 patients with a peripheral blood T-cell clone. Arch Dermatol 1998; 134: 1001-5.
14. Rook AH, Suchin KR, Kao DMF et al. Photopheresis: clinical applications and mechanisms of action. J Invest Dermatol Symp Pwc 1999; 4: 85-90.